Chronic graft versus host disease
MONDO:0020547Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown.It likely results from a complex immune-mediated interaction between the donor and recipient cells.Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.
Also known as: GVHD, chronic, graft versus host disease, chronic, chronic GVHD
115 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
HPV vaccine shows promise for girls on Immune-Suppressing drugs
⭐️ VACCINE ⭐️ CompletedThis study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:36 UTC
-
Could an arthritis drug tame a tough transplant complication?
Disease control CompletedThis study tests the drug abatacept in people with chronic graft-versus-host disease (cGVHD) that is not controlled by steroids. cGVHD is a condition where donor immune cells attack the recipient's body after a stem cell transplant. The trial has two phases: first, to find a safe…
Phase: PHASE1, PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for teens with chronic Graft-Versus-Host disease: belumosudil under study
Disease control CompletedThis study tested the drug belumosudil in Chinese teenagers aged 12 to 18 with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplant. The goal was to see how well the drug works and how safe it is for those who didn't respond to steroids. Six partic…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug shows promise in preventing Graft-Versus-Host disease
Disease control CompletedThis early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Toothpaste aimed at treating chronic mouth sores in transplant patients shows early promise
Disease control CompletedThis completed Phase 1 study tested a special toothpaste containing tacrolimus in 7 patients with oral chronic graft vs. host disease (cGVHD) after a stem cell transplant. Participants used the toothpaste twice daily for three months alongside their usual medications. The goal wa…
Phase: PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy shows promise for tough transplant complication
Disease control CompletedThis study tested adding a low dose of the drug Interleukin-2 (IL-2) to a standard therapy called extracorporeal photopheresis (ECP) for people with chronic graft-versus-host disease (GVHD) that did not respond to steroids. Chronic GVHD is a serious condition where donor immune c…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New hope for transplant patients: drug may tame chronic GVHD without steroids
Disease control CompletedThis study tested the drug ibrutinib as a first treatment for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the recipient's body after a stem cell transplant. Ten adults took ibrutinib daily for up t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for GVHD patients: nilotinib steps in when imatinib fails
Disease control CompletedThis study tested the drug nilotinib in 65 adults with chronic graft-versus-host disease (GVHD) who did not respond to imatinib. GVHD is a complication after a stem cell transplant where donor cells attack the patient's body. The goal was to see if nilotinib could help control th…
Phase: PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo shows promise for kids with transplant complication
Disease control CompletedThis study tested whether adding the drug ruxolitinib to standard steroids helps children with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. 46 children aged 28 days to 18 years took part. The main goal was to see how many had a complete o…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Could a cancer drug ease a devastating transplant complication in kids?
Disease control CompletedThis study tested the drug ibrutinib in 59 children with chronic graft-versus-host disease (cGVHD), a serious condition that can occur after a stem cell transplant. The goal was to find the best dose and see if it is safe. Participants had moderate or severe cGVHD that did not im…
Phase: PHASE1, PHASE2 • Sponsor: Pharmacyclics LLC. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for tough GvHD: pomalidomide shows promise in small trial
Disease control CompletedThis study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD) that didn't improve with standard treatments. GvHD can happen after a stem cell transplant when the donor cells attack the recipient's body. Participants took pomalidomide caps…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New antibody shows promise for Hard-to-Treat GVHD
Disease control CompletedThis trial tested a drug called axatilimab in 41 people with chronic graft-versus-host disease (cGVHD), a complication of stem cell transplants where donor cells attack the patient's body. Participants had already tried at least two other treatments. The study aimed to find a saf…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 17:19 UTC
-
New drug shows promise in preventing transplant complication
Prevention CompletedThis study tested whether the drug obinutuzumab can prevent chronic graft-versus-host disease (cGVHD), a common and serious complication after a stem cell transplant. 181 people who had a stem cell transplant took part. The goal was to see if obinutuzumab could reduce the need fo…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
Scientists track mouth health to unlock secrets of transplant complication
Knowledge-focused CompletedThis study followed 190 adults who had or were about to have a stem cell transplant from a donor. Researchers tracked changes in the mouth, like dryness or sores, to learn more about chronic graft-versus-host disease (cGVHD). Participants provided saliva, mouth swabs, and had den…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Lung transplant infection study aims to improve Long-Term survival
Knowledge-focused CompletedThis study followed 600 lung transplant recipients at the University of Pittsburgh to see how common viral and bacterial infections are and how they affect long-term health. Researchers focused on whether a specific infection (C. pneumoniae) is linked to a condition called bronch…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Mouth may reveal leukemia fight after transplant
Knowledge-focused CompletedThis study looked at 93 people who had a stem cell transplant for blood cancer. Researchers wanted to see if chronic mouth problems (oral cGVHD) could be a simple sign that the new immune system is also attacking the cancer. They followed patients with regular mouth exams before …
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Scientists gather clues on mysterious immune defects
Knowledge-focused CompletedThis study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC